Strides Pharma Science is currently trading at Rs. 366.50, up by 7.10 points or 1.98% from its previous closing of Rs. 359.40 on the BSE.

Strides Pharma Science
Strides Pharma Science

The scrip opened at Rs. 364.85 and has touched a high and low of Rs. 375.00 and Rs. 363.30 respectively. So far 5955 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 10 has touched a 52 week high of Rs. 392.20 on 22-Dec-2022 and a 52 week low of Rs. 268.40 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 379.45 and Rs. 355.05 respectively. The current market cap of the company is Rs. 3245.48 crore.

The promoters holding in the company stood at 28.27%, while Institutions and Non-Institutions held 37.14% and 34.59% respectively.

Strides Pharma Science has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its Puducherry manufacturing facility (Facility), stating the inspection conducted between February 20, 2023 – February 24, 2023 has been closed. The USFDA has classified the facility from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI).

The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019. Strides Puducherry facility caters to the U.S., other regulated markets, and institutional businesses and produces finished dosage formulation products across multiple dosage formats. Consequent to this reclassification by the USFDA, the filed ANDAs from this facility will now start receiving approvals.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.